American Century Companies’s KalVista Pharmaceuticals KALV Stock Holding History

American Century Companies’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,072	Closed	-$85.3K	–	2916
2024 Q4	$85.3K	Sell	10,072 -24,651	-71%	-$255K	﹤0.01%	2849
2024 Q3	$402K	Buy	34,723 +5,784	+20%	+$72.7K	﹤0.01%	2548
2024 Q2	$341K	Sell	28,939 -3,784	-12%	-$44.2K	﹤0.01%	2576
2024 Q1	$388K	Buy	32,723 +3,660	+13%	+$48.8K	﹤0.01%	2539
2023 Q4	$356K	Buy	29,063 +6,910	+31%	+$62.9K	﹤0.01%	2493
2023 Q3	$213K	Buy	22,153 +5,707	+35%	+$58.3K	﹤0.01%	2572
2023 Q2	$148K	Buy	+16,446	New	+$152K	﹤0.01%	2600
2023 Q1	–	Sell	-522,076	Closed	-$3.53M	–	2683
2022 Q4	$3.53M	Sell	522,076 -629	-0.1%	-$3.37K	﹤0.01%	1355
2022 Q3	$7.58M	Buy	522,705 +2,996	+0.6%	+$41.9K	0.01%	986
2022 Q2	$5.11M	Buy	519,709 +35,606	+7%	+$393K	﹤0.01%	1111
2022 Q1	$7.14M	Buy	484,103 +104,870	+28%	+$1.51M	﹤0.01%	1009
2021 Q4	$5.02M	Buy	379,233 +104,380	+38%	+$1.66M	﹤0.01%	1056
2021 Q3	$4.8M	Buy	274,853 +85	+0%	+$1.72K	﹤0.01%	1032
2021 Q2	$6.58M	Buy	274,768 +56,605	+26%	+$1.48M	﹤0.01%	924
2021 Q1	$5.61M	Buy	+218,163	New	+$5.73M	﹤0.01%	910

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

American Century Companies's KALV Position: Q1 2025 in Review

American Century Companies sold out of KalVista Pharmaceuticals (KALV) in Q1 2025, closing a stake of 10,072 shares — an estimated $85.3K sold.

American Century Companies first reported a position in KALV in Q1 2021 and held it in 15 quarters. The position peaked at $7.58M in Q3 2022. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2025.

American Century Companies reported no remaining KalVista Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
American Century Companies sold 10,072 KalVista Pharmaceuticals shares in Q1 2025, an estimated $85.3K.
American Century Companies first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 15 quarters.
American Century Companies's KalVista Pharmaceuticals position peaked at $7.58M in Q3 2022.
128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2025.

Based on American Century Companies's 13F filing for Q1 2025, filed 13 May 2025.